Recombinant CD52 (Alemtuzumab Biosimilar) antibody
The Mouse Monoclonal anti-CD52 (Alemtuzumab Biosimilar) antibody has been validated for FACS and in vivo. It is suitable to detect CD52 (Alemtuzumab Biosimilar) in samples from Human.
Catalog No. ABIN7795101
Quick Overview for Recombinant CD52 (Alemtuzumab Biosimilar) antibody (ABIN7795101)
Target
CD52 (Alemtuzumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Mouse
Clonality
Monoclonal
Conjugate
This CD52 (Alemtuzumab Biosimilar) antibody is un-conjugated
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Alemtuzumab Biosimilar, Human CD52 Monoclonal Antibody
-
Characteristics
- Alemtuzumab Biosimilar uses the same protein sequences as the therapeutic antibody alemtuzumab. Alemtuzumab is a medication used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. In CLL, it has been used as both a first line and second line treatment. In MS it is generally only recommended if other treatments have not worked. It is given by injection into a vein. It is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived. After treatment with alemtuzumab, these CD52-bearing lymphocytes are targeted for destruction.
-
Purification
- Protein A or G affinity column
-
Purity
- >95 % by reducing SDS-PAGE
-
Endotoxin Level
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogen
- Human CD52
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- > 3 mg/mL
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- CD52 (Alemtuzumab Biosimilar)
-
Alternative Name
- Alemtuzumab Biosimilar
-
Target Type
- Biosimilar
Target
-
You are here:
